Therakind enters exclusive distribution partnership with Pharmapal
Access to Jylamvo continues to broaden access in Saudi Arabia, Kuwait, Jordan and Tunisia
30 October 2019 - Therakind Limited, a specialty pharmaceutical company focused on developing niche medicines for difficult-to-treat patient groups, has entered into an exclusive distribution agreement with Pharmapal Drug Store LLC for Therakind’s lead product, Jylamvo.
Under this agreement, Pharmapal secures exclusive rights to market, commercialise and sell Jylamvo in Saudi Arabia, Kuwait, Jordan and Tunisia. Jylamvo is already on sale in UK, Greece, Poland and Romania.
Jylamvo is a novel methotrexate 2mg/ml Oral Solution which is licensed for use in adults and children over three years old for the treatment of rheumatological disorders (adult and juvenile) and adult psoriasis and psoriatic arthritis, and for the maintenance treatment of acute lymphoblastic leukaemia (ALL). Jylamvo has a marketing authorization which allows it to be sold throughout the European Economic Area and is the first oral liquid formulation of methotrexate to be authorised in Europe for the treatment of polyarthritic juvenile idiopathic arthritis (JIA).
Jylamvo as an oral liquid is easier for patients with swallowing difficulties to take than tablets and its use eliminates dosing inaccuracies and unnecessary exposure to the cytotoxic methotrexate powder which may occur if tablets are crushed. As a licensed oral liquid, Jylamvo has proven stability and no inappropriate excipients which may be the case with unlicensed oral liquids. Jylamvo also has a palatable orange taste which masks methotrexate’s bitter taste. It also addresses compliance issues which may occur with methotrexate injections due to patients’ fear of needles and intolerance of injection site pain and reaction.
Dr Susan Conroy, CEO of Therakind, said:
“This partnership with Pharmapal further strengthens our reach across the UAE. Our focus is to provide age-specific medicines designed to account for impact of dosage in different age groups. Jylamvo is an easy to take, pleasant tasting liquid medicine for children and adults which will simplify their treatment regime. With Pharmapal’s expertise and network our vision is to improve patient care for all.”
Enquiries:
Therakind Limited
Susan Conroy, Chief Executive Officer
Sam Race, Finance Director
Tel: +44 (0)208 346 6035
Email: admin@therakind.com
Notes to Editors
About Pharmapal Drug Store LLC
Pharmapal Drug Store LLC was founded in 1998, as a full-service distributor handling exclusive products tailor-made to meet the demands of the middle east in its fast-growing landscape and continuous developments in the healthcare industry. Pharmapal distributes and sells in the middle east with its network of well-trained medical representatives and partnership with leading pharmaceutical and para-pharmaceutical groups ensuring the full coverage of the region. The company takes pride in its deeply rooted values to provide innovation & excellence in the service of better health to all.
